Seguir
Katherine Riccione
Katherine Riccione
Biomedical Engineering, Duke University
No hay ninguna dirección de correo electrónico verificada.
Título
Citado por
Citado por
Año
The inoculum effect and band‐pass bacterial response to periodic antibiotic treatment
C Tan, R Phillip Smith, JK Srimani, KA Riccione, S Prasada, M Kuehn, ...
Molecular systems biology 8 (1), 617, 2012
1192012
Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma
EA Reap, CM Suryadevara, KA Batich, L Sanchez-Perez, GE Archer, ...
Cancer research 78 (1), 256-264, 2018
1012018
Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
CM Suryadevara, R Desai, ML Abel, KA Riccione, KA Batich, SH Shen, ...
Oncoimmunology 7 (6), e1434464, 2018
902018
Programmed Allee effect in bacteria causes a tradeoff between population spread and survival
R Smith, C Tan, JK Srimani, A Pai, KA Riccione, H Song, L You
Proceedings of the National Academy of Sciences 111 (5), 1969-1974, 2014
762014
A synthetic biology approach to understanding cellular information processing
KA Riccione, RP Smith, AJ Lee, L You
ACS synthetic biology 1 (9), 389-402, 2012
362012
Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care
K Riccione, CM Suryadevara, D Snyder, X Cui, JH Sampson, ...
JoVE (Journal of Visualized Experiments), e52397, 2015
242015
Antibody-based immunotherapy for malignant glioma
PC Gedeon, KA Riccione, PE Fecci, JH Sampson
Seminars in oncology 41 (4), 496-510, 2014
182014
Immunotherapy gone viral: bortezomib and oHSV enhance antitumor NK-cell activity
CM Suryadevara, KA Riccione, JH Sampson
Clinical Cancer Research 22 (21), 5164-5166, 2016
162016
CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response
KA Riccione, LZ He, PE Fecci, PK Norberg, CM Suryadevara, A Swartz, ...
Oncoimmunology 7 (12), e1502904, 2018
132018
A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope
AM Swartz, KL Congdon, SK Nair, QJ Li, JE Herndon, CM Suryadevara, ...
npj Vaccines 6 (1), 12, 2021
82021
Checkpoint Blockade Immunotherapy for Glioblastoma: Progress and Challenges
KA Riccione, P Gedeon, L Sanchez-Perez, JH Sampson
Translational Immunotherapy of Brain Tumors, 261-300, 2017
32017
IDH1 mutations as a immunotherapeutic target for brain tumors
GE Archer, E Reap, P Norberg, X Cui, R Schmittling, J Herndon, ...
Neuro-oncology 16 (suppl_3), iii40-iii40, 2014
22014
Synthetic long peptide vaccines possessing a universal helper epitope can unmask the therapeutic effects of MHC I-restricted neoepitopes
A Swartz, K Riccione, K Congdon, LA Sanchez-Perez, SK Nair, ...
The Journal of Immunology 204 (1_Supplement), 91.26-91.26, 2020
12020
DEVELOPMENT OF A PEPTIDE VACCINE PLATFORM FOR BRAIN TUMOR IMMUNOTHERAPY THAT INCORPORATES ADJUVANT CD27 STIMULATION FOR ENHANCED T CELL IMMUNITY
K Riccione, L Riccione, JH Sampson
NEURO-ONCOLOGY 18, 98-98, 2016
12016
TMOD-14. CONJOINED CLASS I AND II EPITOPES ENHANCE NEOANTIGEN-TARGETED ACTIVE IMMUNOTHERAPY
A Swartz, K Congdon, S Nair, QJ Li, J Herndon, C Suryadevara, ...
Neuro-Oncology 23 (Supplement_6), vi218-vi218, 2021
2021
An Agonist CD27 Antibody for Brain Tumor Immunotherapy
KA Riccione
Duke University, 2017
2017
IMST-38. CAR T CELLS INDUCE COMPLETE REGRESSION OF MURINE GLIOBLASTOMA AFTER PRECONDITIONING HOSTS WITH TEMOZOLOMIDE
CM Suryadevara, P Chongsathidkiet, K Riccione, PC Gedeon, R Desai, ...
Neuro-Oncology 18 (suppl_6), vi94-vi95, 2016
2016
Immunotherapy for gliomas
PE Fecci, K Riccione, GP Dunn, E Reap, G Vlahovic, K Congdon, ...
The Duke Glioma Handbook: Pathology, Diagnosis, and Management, 91-120, 2016
2016
Characterization of a human CD27 agonistic monoclonal antibody for use as an agent in glioblastoma therapy (P4411)
K Riccione, L Sanchez-Perez, C Flores, J Sampson
The Journal of Immunology 190 (1_Supplement), 205.15-205.15, 2013
2013
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–19